Pfizer almost always beats consensus earnings expectations. That should be true for Q4-12 given the unexpected strength in the euro.
However, the stock doesn't move much on actual earnings results; it's the GUIDANCE that is much more important. Unfortunately, management believes in giving VERY CONSERVATIVE GUIDANCE initially. That generally doesn't go over very well on Wall Street.
So despite an expected earnings beat for Q4, I am expecting something of a correction when analysts and investors get a load of the very tepid guidance that I also expect.